Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 2/20 | 0.40 |
| ▸ | PDE8B | O95263 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1991177 | 1.00 | HSD17B10 (0.45) | HSD17B10HPGDSMN1; SMN2EPHX1ALDH1A1 | |
| SCHEMBL1991179 | 1.00 | HSD17B10 (0.45) | HSD17B10HPGDSMN1; SMN2EPHX1ALDH1A1 | |
| SCHEMBL25980668 | 0.98 | HPGD (0.47) | HSD17B10HPGDSMN1; SMN2EPHX1ALDH1A1 | |
| SCHEMBL31336384 | 0.98 | HPGD (0.47) | HSD17B10HPGDSMN1; SMN2EPHX1ALDH1A1 | |
| SCHEMBL14398395 | 0.98 | HPGD (0.47) | HSD17B10HPGDSMN1; SMN2EPHX1ALDH1A1 | |
| SCHEMBL338312 | 0.95 | HSD17B10 (0.49) | HSD17B10HPGDSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL40804 | 0.95 | HSD17B10 (0.49) | HSD17B10HPGDSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL190173 | 0.95 | HSD17B10 (0.49) | HSD17B10HPGDSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL2030521 | 0.88 | HSD17B10 (0.41) | HSD17B10HPGDSMN1; SMN2EPHX1ALDH1A1 | |
| SCHEMBL17980096 | 0.88 | HSD17B10 (0.41) | HSD17B10HPGDSMN1; SMN2EPHX1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078121-A1 | INHIBITORS OF ENL/AF9 YEATS AND FLT3 | BRIDGE MEDICINES (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4463452-B1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC (US) | 2025-07-30 | — | — | EP | disclosed |
| EP-4583869-A2 | INHIBITORS OF ENL/AF9 YEATS AND FLT3 | Bridge Medicines (US) | 2025-07-16 | — | — | EP | disclosed |
| US-12344600-B2 | c-Myc mRNA translation modulators and uses thereof in the treatment of cancer | ANIMA BIOTECH INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | BRIDGE MEDICINES | 2025-05-01 | — | — | US | disclosed |
| US-20250109128-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-04-03 | — | — | US | disclosed |
| US-20250002471-A1 | 6-SUBSTITUTED INDOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2025-01-02 | — | — | US | disclosed |
| EP-4217361-B1 | COMPOUNDS AS MODULATORS OF ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1 (ERAP1) | GREY WOLF THERAPEUTICS LTD (GB) | 2024-12-25 | — | — | EP | disclosed |
| CN-118894859-A | DNA polymerase theta inhibitor, intermediate thereof, preparation method and application thereof | 上海旭成医药科技有限公司 | 2024-11-05 | — | — | CN | disclosed |
| US-20240300976-A1 | COMPOUNDS AS MODULATORS OF ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1 (ERAP1) | Grey Wolf Therapeutics Limited (GB) | 2024-09-12 | — | — | US | disclosed |
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | disclosed |
| WO-2007130820-A2 | MGLUR5 MODULATORS I | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| WO-2007039782-A1 | TETRAZOLE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2007-04-12 | — | — | WO | disclosed |
| WO-1991000724-A1 | ALKYNYL AMINES THAT REGULATE CHOLINERGIC NEUROTRANSMISSION | ABBOTT LABORATORIES (US) | 1991-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259862-A1 | MGluR5 modulators I | GRM5, GRM1, GRIK5 | HSD17B10 2742/4885HPGD 2472/4885SMN1; SMN2 1207/4885 |
| US-20070259916-A1 | mGluR5 modulators II | GRM5, GRM2, GRIK5 | HSD17B10 2632/4885HPGD 2431/4885SMN1; SMN2 1076/4885 |
| US-20250002471-A1 | 6-SUBSTITUTED INDOLE COMPOUNDS | SSB, IDO1, IDO2 | HSD17B10 3432/4885HPGD 961/4885SMN1; SMN2 4691/4885 |
| US-20240300976-A1 | COMPOUNDS AS MODULATORS OF ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1 (ERAP1) | ERAP1, ERAP2, ERMP1 | HSD17B10 493/4885HPGD 1936/4885SMN1; SMN2 3271/4885 |
| US-12344600-B2 | c-Myc mRNA translation modulators and uses thereof in the treatment of cancer | MYC, MYCBP, MYCBP2 | HSD17B10 4513/4885HPGD 4555/4885SMN1; SMN2 3115/4885 |
| US-20260078121-A1 | INHIBITORS OF ENL/AF9 YEATS AND FLT3 | MLLT3, MLLT1, FLT3 | HSD17B10 2268/4885HPGD 4318/4885SMN1; SMN2 4179/4885 |
| US-20250109128-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | HSD17B10 4513/4885HPGD 4555/4885SMN1; SMN2 3115/4885 |
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | MLLT3, MLLT1, YEATS2 | HSD17B10 2328/4885HPGD 4028/4885SMN1; SMN2 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.